Stay updated on Lintuzumab-Ac225 in Older AML Patients Clinical Trial
Sign up to get notified when there's something new on the Lintuzumab-Ac225 in Older AML Patients Clinical Trial page.

Latest updates to the Lintuzumab-Ac225 in Older AML Patients Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedSignificant: there is an updated operating-status notice and a new version (v3.2.0) replacing v3.1.0. This informs users about potential delays, open status of NIH Clinical Center, and directs to cc.nih.gov and opm.gov for updates.SummaryDifference3%

- Check34 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

- Check48 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.2%

- Check55 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, and a 'Back to Top' feature has been added.SummaryDifference0.2%

- Check63 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, along with a comprehensive list of drug information, particularly various chemical compounds and medications. However, many specific medical topics and related resources have been removed.SummaryDifference5%

- Check70 days agoChange DetectedThe web page now includes information about a Phase I trial of alpha-particle immunotherapy involving 225Ac-lintuzumab and low-dose cytarabine for patients aged 60 or older with untreated acute myeloid leukemia.SummaryDifference1%

Stay in the know with updates to Lintuzumab-Ac225 in Older AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lintuzumab-Ac225 in Older AML Patients Clinical Trial page.